UPDATE: Krystal Biotech (KRYS) Prices 2.275M Share Common Offering at $55/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
May 18, 2020 9:57 PM EDTPITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the Company), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously announced underwritten public offering of 2,275,000 shares of its common stock, at a public offering price of $55.00 per share. The Company granted the underwriters a 30-day option to purchase up to an additional 341,250 shares of its common stock. The gross proceeds to the Company from this offering are expected to be approximately $125.1 million, before... More
